Department of Obstetrics and Gynecology, University of Texas Medical Branch at Galveston, Galveston, TX.
Department of Obstetrics and Gynecology, University of Texas Medical Branch at Galveston, Galveston, TX.
Am J Obstet Gynecol. 2019 Mar;220(3):275.e1-275.e9. doi: 10.1016/j.ajog.2019.01.008. Epub 2019 Feb 18.
The objective of the study was to test the hypothesis that Dilapan-S is not inferior to the Foley balloon for preinduction cervical ripening at term.
Pregnant women ≥37 weeks scheduled for induction with unfavorable cervix (≤3 cm dilated and ≤60% effaced) were randomly assigned to 12 hours of either Foley balloon inflated with 60 mL saline or Dilapan-S for cervical ripening. If the cervix remained unfavorable, then 1 more round of the assigned dilator was used. Management following ripening was left up to the clinical providers. The primary outcome was vaginal delivery. A satisfaction survey was also obtained after the preinduction period. Sample size was based on a noninferiority margin of 10%, 90% power, and an estimated frequency of vaginal delivery of 71% in Foley balloon and 76% in Dilapan-S.
From November 2016 through February 2018, 419 women were randomized (209 to Foley balloon; 210 to Dilapan-S). In the intent-to-treat analysis, vaginal delivery was more common in Dilapan-S vs Foley balloon (81.3% vs 76.1%), with an absolute difference with respect to the Foley balloon of 5.2% (95% confidence interval, -2.7% to 13.0%) indicating noninferiority for the prespecified margin. The difference was not large enough to show superiority. Noninferiority was confirmed in the per-protocol population (n = 204 in the Foley balloon, n = 188 in Dilapan-S), supporting the robustness of the results. Secondary outcomes were not different between groups, except for a longer time the device remained in place in Dilapan-S compared with the Foley balloon. Maternal and neonatal adverse events were not significantly different between groups. A priori interaction analyses showed no difference in the effect on vaginal delivery by cervical dilation at randomization, parity, or body mass index >30 kg/m. Patients with Dilapan-S were more satisfied than patients with the Foley balloon as far as sleep (P = .01), relaxing time (P = .001), and performance of desired daily activities (P = .001).
Dilapan-S is not inferior to the Foley balloon for preinduction cervical ripening at term. Advantages of Dilapan-S over Foley include Food and Drug Administration approval, safe profile, no protrusion from the introitus, no need to keep under tension, and better patient satisfaction.
本研究旨在验证以下假设,即与 Foley 球囊相比,Dilapan-S 在足月引产时用于宫颈成熟并不差。
选择≥37 周、宫颈不成熟(扩张<3cm,<60%展平)拟行引产的孕妇,随机分为 Foley 球囊组(生理盐水 60mL 充盈)或 Dilapan-S 组 12 小时,用于宫颈成熟。如果宫颈仍不成熟,可再使用一轮指定的扩张器。成熟后处理方法由临床医生决定。主要结局是阴道分娩。诱导前还进行了满意度调查。样本量基于非劣效性边界 10%、90%效能和 Foley 球囊估计的阴道分娩率 71%、Dilapan-S 为 76%。
2016 年 11 月至 2018 年 2 月,419 名孕妇随机分组(Foley 球囊组 209 例,Dilapan-S 组 210 例)。意向治疗分析显示,Dilapan-S 组阴道分娩率高于 Foley 球囊组(81.3% vs 76.1%),Foley 球囊组的绝对差异为 5.2%(95%置信区间,-2.7%至 13.0%),表明符合预设边界的非劣效性。但差异不足以显示优越性。在方案人群(Foley 球囊组 204 例,Dilapan-S 组 188 例)中也证实了非劣效性,支持结果的稳健性。次要结局在两组间无差异,除了 Dilapan-S 组的设备保留时间长于 Foley 球囊组。两组间的母婴不良事件无显著差异。预先进行的交互分析显示,随机化时宫颈扩张、产次或 BMI>30kg/m2 对阴道分娩的影响无差异。与 Foley 球囊组相比,Dilapan-S 组的患者在睡眠(P=0.01)、放松时间(P=0.001)和日常活动表现(P=0.001)方面的满意度更高。
与 Foley 球囊相比,Dilapan-S 在足月引产时用于宫颈成熟并不差。与 Foley 球囊相比,Dilapan-S 的优势在于获得美国食品和药物管理局批准、安全性好、不会从阴道突出、无需保持张力、患者满意度更高。